2021 Q4 Form 10-K Financial Statement

#000095017022003946 Filed on March 16, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $118.3M $295.8M $0.00
YoY Change 185.98%
Cost Of Revenue $102.5M $264.3M
YoY Change
Gross Profit $15.84M $31.45M
YoY Change
Gross Profit Margin 13.39% 10.63%
Selling, General & Admin $18.93M $45.53M $3.741M
YoY Change 405.97% 1035.04%
% of Gross Profit 119.52% 144.79%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $6.070M $2.800M
YoY Change 226.34%
% of Gross Profit 38.33% 8.9%
Operating Expenses $25.02M $324.6M $3.741M
YoY Change 568.71% 246.26%
Operating Profit -$9.181M -$28.82M
YoY Change -397.69%
Interest Expense $6.830M -$4.492M -$17.54M
YoY Change -138.93% 170.77%
% of Operating Profit
Other Income/Expense, Net -$495.0K -$1.333M
YoY Change
Pretax Income -$3.397M -$6.516M -$21.28M
YoY Change -84.04% -186.05%
Income Tax $159.0K $159.0K
% Of Pretax Income
Net Earnings -$3.556M -$6.675M -$21.28M
YoY Change -83.29% -187.82%
Net Earnings / Revenue -3.01% -2.26%
Basic Earnings Per Share -$0.13
Diluted Earnings Per Share -$40.44K -$0.13 -$1.050M
COMMON SHARES
Basic Shares Outstanding 52.62M
Diluted Shares Outstanding 52.62M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.92M $47.92M $908.7K
YoY Change 5173.08% 5173.08%
Cash & Equivalents $47.92M $4.934M
Short-Term Investments
Other Short-Term Assets $17.58M $17.58M $198.2K
YoY Change 8770.67% 8770.67%
Inventory $550.0K $550.0K $15.00K
Prepaid Expenses $17.04M $183.0K
Receivables $42.00M $42.00M $9.395M
Other Receivables $0.00 $0.00
Total Short-Term Assets $108.0M $108.0M $14.88M
YoY Change 626.05% 9661.13%
LONG-TERM ASSETS
Property, Plant & Equipment $15.99M $15.99M $4.796M
YoY Change 233.47%
Goodwill $464.6M $10.07M
YoY Change 4514.28%
Intangibles $59.81M $8.575M
YoY Change 597.5%
Long-Term Investments $143.8M
YoY Change
Other Assets $2.706M $4.678M $183.0K
YoY Change 1378.69%
Total Long-Term Assets $545.0M $545.0M $23.62M
YoY Change 2207.37% 278.94%
TOTAL ASSETS
Total Short-Term Assets $108.0M $108.0M $14.88M
Total Long-Term Assets $545.0M $545.0M $23.62M
Total Assets $653.1M $653.1M $38.50M
YoY Change 1596.21% 350.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.110M $3.110M $1.044M
YoY Change 197.89% 578.8%
Accrued Expenses $8.690M $8.690M $2.572M
YoY Change 237.87% 174.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.275M $6.275M $1.004M
YoY Change 525.0%
Total Short-Term Liabilities $21.96M $21.96M $5.451M
YoY Change 302.84% 484.63%
LONG-TERM LIABILITIES
Long-Term Debt $111.0M $111.0M $26.33M
YoY Change 321.5%
Other Long-Term Liabilities $6.428M $14.80M $29.21M
YoY Change -77.99% -49.32%
Total Long-Term Liabilities $117.4M $125.8M $26.33M
YoY Change 345.92% 330.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.96M $21.96M $5.451M
Total Long-Term Liabilities $117.4M $125.8M $26.33M
Total Liabilities $147.7M $147.7M $31.78M
YoY Change 364.89% 348.14%
SHAREHOLDERS EQUITY
Retained Earnings $33.00K
YoY Change
Common Stock $505.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $505.4M $505.4M $6.727M
YoY Change
Total Liabilities & Shareholders Equity $653.1M $653.1M $38.50M
YoY Change 1596.21% 350.58%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$3.556M -$6.675M -$21.28M
YoY Change -83.29% -187.82%
Depreciation, Depletion And Amortization $6.070M $2.800M
YoY Change 226.34%
Cash From Operating Activities -$15.05M -$23.86M -$78.88K
YoY Change 18984.69% -548.76%
INVESTING ACTIVITIES
Capital Expenditures -$3.905M $3.990M
YoY Change 85.5%
Acquisitions
YoY Change
Other Investing Activities -$11.36M -$309.7M $0.00
YoY Change 115.45%
Cash From Investing Activities -$15.27M -$316.6M $0.00
YoY Change 4460.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $415.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.212M 383.4M 0.000
YoY Change 17960.2%
NET CHANGE
Cash From Operating Activities -15.05M -23.86M -78.88K
Cash From Investing Activities -15.27M -316.6M 0.000
Cash From Financing Activities -2.212M 383.4M 0.000
Net Change In Cash -32.53M 42.98M -78.88K
YoY Change 41144.93% 8548.49%
FREE CASH FLOW
Cash From Operating Activities -$15.05M -$23.86M -$78.88K
Capital Expenditures -$3.905M $3.990M
Free Cash Flow -$11.15M -$27.85M
YoY Change -979.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1216000
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001813914
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39391
CY2021 dei Entity Registrant Name
EntityRegistrantName
CareMax, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0992224
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
1000 NW 57 Court
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Miami
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33126
CY2021 dei City Area Code
CityAreaCode
786
CY2021 dei Local Phone Number
LocalPhoneNumber
360-4768
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
687516271
CY2021 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2021 dei Auditor Location
AuditorLocation
Red Bank, New Jersey
CY2021 dei Auditor Firm
AuditorFirmId
100
CY2021Q4 us-gaap Cash
Cash
47917000
CY2020Q4 us-gaap Cash
Cash
4934000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
41998000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9395000
CY2021Q4 us-gaap Inventory Net
InventoryNet
550000
CY2020Q4 us-gaap Inventory Net
InventoryNet
15000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
17040000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
183000
CY2021Q4 cmax Risk Settlements Due From Providers Current
RiskSettlementsDueFromProvidersCurrent
539000
CY2020Q4 cmax Risk Settlements Due From Providers Current
RiskSettlementsDueFromProvidersCurrent
80000
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
274000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
108044000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
14881000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15993000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4796000
CY2021Q4 us-gaap Goodwill
Goodwill
464566000
CY2020Q4 us-gaap Goodwill
Goodwill
10068000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
59811000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8575000
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
1972000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2706000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
183000
CY2021Q4 us-gaap Assets
Assets
653092000
CY2020Q4 us-gaap Assets
Assets
38503000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3110000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1044000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8686000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2572000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
149000
CY2021Q4 cmax Risk Settlements Due To Providers Current
RiskSettlementsDueToProvidersCurrent
196000
CY2020Q4 cmax Risk Settlements Due To Providers Current
RiskSettlementsDueToProvidersCurrent
643000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
6275000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1004000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
39000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3687000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21959000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5451000
CY2021Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
8375000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
110960000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26325000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6428000
CY2021Q4 us-gaap Liabilities
Liabilities
147722000
CY2020Q4 us-gaap Liabilities
Liabilities
31776000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
505327000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
33000
CY2020Q4 cmax Common Unit Par Or Stated Value Per Share
CommonUnitParOrStatedValuePerShare
0
CY2020Q4 us-gaap Common Unit Authorized
CommonUnitAuthorized
200
CY2020Q4 us-gaap Common Unit Issued
CommonUnitIssued
200
CY2020Q4 us-gaap Common Unit Outstanding
CommonUnitOutstanding
200
CY2020Q4 us-gaap Common Unit Issuance Value
CommonUnitIssuanceValue
223000
CY2020Q4 us-gaap Members Capital
MembersCapital
6504000
CY2021Q4 us-gaap Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest
LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest
505370000
CY2020Q4 us-gaap Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest
LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest
6727000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
653092000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38503000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
295762000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103421000
CY2021 cmax Health Care Organization External Provider Costs
HealthCareOrganizationExternalProviderCosts
206747000
CY2020 cmax Health Care Organization External Provider Costs
HealthCareOrganizationExternalProviderCosts
66050000
CY2021 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
57566000
CY2020 us-gaap Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
17373000
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4955000
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1067000
CY2021 cmax Corporate General And Administrative
CorporateGeneralAndAdministrative
40579000
CY2020 cmax Corporate General And Administrative
CorporateGeneralAndAdministrative
7748000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
13216000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1501000
CY2021 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1522000
CY2020 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0
CY2021 us-gaap Operating Expenses
OperatingExpenses
324585000
CY2020 us-gaap Operating Expenses
OperatingExpenses
93739000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-28822000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
9682000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4492000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1659000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20757000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2021 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-5794000
CY2020 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-50000
CY2020 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1630000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-451000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1333000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6516000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7572000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
159000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Profit Loss
ProfitLoss
-6675000
CY2020 us-gaap Profit Loss
ProfitLoss
7572000
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2020 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-29000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-6675000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
7601000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6675000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
7601000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52620980
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10796069
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52620980
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10796069
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.70
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
505370000
CY2021 us-gaap Profit Loss
ProfitLoss
-6675000
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.70
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
4946000
CY2020 us-gaap Profit Loss
ProfitLoss
7572000
CY2020 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
2100000
CY2020 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
3691000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
6727000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
6727000
CY2021 cmax Net Income Loss Prior To Business Combination
NetIncomeLossPriorToBusinessCombination
-5185000
CY2021 cmax Stock Issued During Period Value For Contingent Issuable Stock Upon First Share Price Trigger On Earnout Shares
StockIssuedDuringPeriodValueForContingentIssuableStockUponFirstSharePriceTriggerOnEarnoutShares
39110000
CY2021 cmax Additional Paid In Capital Adjustments Related Reclassification Of Contingent Consideration Previously Liability Classified
AdditionalPaidInCapitalAdjustmentsRelatedReclassificationOfContingentConsiderationPreviouslyLiabilityClassified
45088000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6650000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1341000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
12883000
CY2021 cmax Net Income Loss After Business Combination
NetIncomeLossAfterBusinessCombination
-1490000
CY2020 us-gaap Profit Loss
ProfitLoss
7572000
CY2021 us-gaap Depreciation
Depreciation
2813000
CY2020 us-gaap Depreciation
Depreciation
858000
CY2021 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
10402000
CY2020 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
643000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
866000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
177000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1341000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
0
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20757000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2021 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-5794000
CY2020 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1630000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-451000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-331000
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3836000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4208000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
85000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5000
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
768000
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-6000
CY2021 cmax Increase Decrease In Risk Settlements Due From Due To Providers
IncreaseDecreaseInRiskSettlementsDueFromDueToProviders
459000
CY2020 cmax Increase Decrease In Risk Settlements Due From Due To Providers
IncreaseDecreaseInRiskSettlementsDueFromDueToProviders
-248000
CY2021 cmax Increase Decrease In Due To From Related Parties
IncreaseDecreaseInDueToFromRelatedParties
235000
CY2020 cmax Increase Decrease In Due To From Related Parties
IncreaseDecreaseInDueToFromRelatedParties
-146000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1501000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-12000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-984000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-686000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
394000
CY2021 us-gaap Payments To Acquire Additional Interest In Subsidiaries
PaymentsToAcquireAdditionalInterestInSubsidiaries
0
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1574000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
CY2021 cmax Increase Decrease In Accrued Interest
IncreaseDecreaseInAccruedInterest
-145000
CY2020 cmax Increase Decrease In Accrued Interest
IncreaseDecreaseInAccruedInterest
0
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23856000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5316000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3990000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2151000
CY2021 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
309707000
CY2020 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
2566000
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2882000
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
CY2021 cmax Payment Of Asset Purchase Agreement Holdback
PaymentOfAssetPurchaseAgreementHoldback
0
CY2020 cmax Payment Of Asset Purchase Agreement Holdback
PaymentOfAssetPurchaseAgreementHoldback
329000
CY2020 us-gaap Payments To Acquire Additional Interest In Subsidiaries
PaymentsToAcquireAdditionalInterestInSubsidiaries
1897000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-316579000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6942000
CY2021 cmax Borrowing Under Revolving Loan Commitment
BorrowingUnderRevolvingLoanCommitment
0
CY2020 cmax Borrowing Under Revolving Loan Commitment
BorrowingUnderRevolvingLoanCommitment
4075000
CY2021 cmax Loan From Paycheck Protection Program
LoanFromPaycheckProtectionProgram
0
CY2020 cmax Loan From Paycheck Protection Program
LoanFromPaycheckProtectionProgram
2164000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
415000000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
12471000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2021 cmax Reverse Recapitalization
ReverseRecapitalization
108435000
CY2020 cmax Reverse Recapitalization
ReverseRecapitalization
0
CY2021 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
125000000
CY2020 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
0
CY2021 cmax Principal Payments On Long Term Debt
PrincipalPaymentsOnLongTermDebt
27711000
CY2020 cmax Principal Payments On Long Term Debt
PrincipalPaymentsOnLongTermDebt
425000
CY2021 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
7478000
CY2020 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2021 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
487000
CY2020 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0
CY2021 us-gaap Distribution Made To Limited Liability Company Llc Member Cash Distributions Paid
DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid
0
CY2020 us-gaap Distribution Made To Limited Liability Company Llc Member Cash Distributions Paid
DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid
3691000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
383418000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2123000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42983000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
497000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4934000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4438000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47917000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4934000
CY2021 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
188678000
CY2020 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
0
CY2021 cmax Contingent Consideration Issued In Business Combination
ContingentConsiderationIssuedInBusinessCombination
38348000
CY2020 cmax Contingent Consideration Issued In Business Combination
ContingentConsiderationIssuedInBusinessCombination
0
CY2021 cmax Purchase Of Non Controlling Interest Through Accounts Payable In Noncash Or Partial Noncash Transaction
PurchaseOfNonControllingInterestThroughAccountsPayableInNoncashOrPartialNoncashTransaction
0
CY2020 cmax Purchase Of Non Controlling Interest Through Accounts Payable In Noncash Or Partial Noncash Transaction
PurchaseOfNonControllingInterestThroughAccountsPayableInNoncashOrPartialNoncashTransaction
203000
CY2021 cmax Payroll Protection Program Loan Forgiveness
PayrollProtectionProgramLoanForgiveness
2164000
CY2020 cmax Payroll Protection Program Loan Forgiveness
PayrollProtectionProgramLoanForgiveness
0
CY2021 cmax Equity Warrant Consideration Issued
EquityWarrantConsiderationIssued
14533000
CY2020 cmax Equity Warrant Consideration Issued
EquityWarrantConsiderationIssued
0
CY2021 us-gaap Interest Paid Net
InterestPaidNet
4423000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
1251000
CY2021 cmax Acquisition Of Business Financed Through Deferred Consideration
AcquisitionOfBusinessFinancedThroughDeferredConsideration
0
CY2020 cmax Acquisition Of Business Financed Through Deferred Consideration
AcquisitionOfBusinessFinancedThroughDeferredConsideration
450000
CY2021 cmax Purchase Of Property And Equipment Through Long Term Debt
PurchaseOfPropertyAndEquipmentThroughLongTermDebt
0
CY2020 cmax Purchase Of Property And Equipment Through Long Term Debt
PurchaseOfPropertyAndEquipmentThroughLongTermDebt
50000
CY2021 cmax Debt Issuance And Interest Costs Paid Through Long Term Debt
DebtIssuanceAndInterestCostsPaidThroughLongTermDebt
0
CY2020 cmax Debt Issuance And Interest Costs Paid Through Long Term Debt
DebtIssuanceAndInterestCostsPaidThroughLongTermDebt
399000
CY2021 cmax Extinguishment Of Long Term Debt Through New Debt Proceeds
ExtinguishmentOfLongTermDebtThroughNewDebtProceeds
0
CY2020 cmax Extinguishment Of Long Term Debt Through New Debt Proceeds
ExtinguishmentOfLongTermDebtThroughNewDebtProceeds
2500000
CY2021 cmax Acquisition Of Business Financed Through Long Term Debt
AcquisitionOfBusinessFinancedThroughLongTermDebt
0
CY2020 cmax Acquisition Of Business Financed Through Long Term Debt
AcquisitionOfBusinessFinancedThroughLongTermDebt
6051000
CY2021 cmax Number Of Wholly Owned Operating Multi Specialty Medical Centers
NumberOfWhollyOwnedOperatingMultiSpecialtyMedicalCenters
45
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The areas where significant estimates are used in the accompanying financial statements include, but are not limited to, purchase price allocations, including fair value estimates of intangibles and contingent consideration; the valuation of and related impairment recognitions of long-lived assets; the valuation of the derivative warrant liabilities; the estimated useful lives of fixed assets and intangible assets, including internally developed software; settlements related to revenue and the revenue accrual and accrued expenses. Actual results could differ from those estimates.</span></p>
CY2021 cmax Number Of Portfolio
NumberOfPortfolio
1
CY2021 us-gaap Revenue Practical Expedient Financing Component
RevenuePracticalExpedientFinancingComponent
true
CY2021 us-gaap Revenue Practical Expedient Incremental Cost Of Obtaining Contract
RevenuePracticalExpedientIncrementalCostOfObtainingContract
true
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk and Significant Customers</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and accounts receivable. The Company’s cash balances with individual banking institutions are in excess of federally insured limits from time to time. The Company believes it is not exposed to any significant concentrations of credit risk from these financial instruments. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Anthem, Inc. ("Anthem") represented approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s accounts receivable balance as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and December 31, 2020, respectively. Anthem represented </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s revenues for the three months ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020 and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s revenues for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">twelve months ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span></p>
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
106700000
CY2021 cmax Reinsurance Premium Expense Incurred
ReinsurancePremiumExpenseIncurred
10900000
CY2020 cmax Reinsurance Premium Expense Incurred
ReinsurancePremiumExpenseIncurred
10300000
CY2021 cmax Reinsurance Recoveries Recognized
ReinsuranceRecoveriesRecognized
14700000
CY2020 cmax Reinsurance Recoveries Recognized
ReinsuranceRecoveriesRecognized
11200000
CY2020Q4 us-gaap Goodwill
Goodwill
10068000
CY2021 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
454498000
CY2021Q4 us-gaap Goodwill
Goodwill
464566000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
71141000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11331000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
59811000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
9494000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
919000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8575000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10400000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
645000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
15134000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
12234000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
10199000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
8547000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
7616000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
6082000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21902000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7892000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5909000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3096000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15993000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4796000
CY2021 cmax Estimated Capital Expenditures To Complete Construction In Progress
EstimatedCapitalExpendituresToCompleteConstructionInProgress
500000
CY2021 us-gaap Depreciation
Depreciation
2800000
CY2020 us-gaap Depreciation
Depreciation
858000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4704000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
377000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
117236000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
27329000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
6275000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1004000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
110960000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26325000
CY2021 us-gaap Debt Instrument Interest Rate Terms
DebtInstrumentInterestRateTerms
Interest is payable on the outstanding loans under the Credit Facilities based on, at the option of the Company, either: (i) Eurocurrency (with a LIBOR floor of 0.75% per annum) plus variable spreads ranging from 2.75% to 3.50% per annum based on first lien net leverage ratio levels or (ii) the Alternate Base Rate (defined as the highest of (a) the Prime Rate (as defined in the Credit Agreement and established by the Agent), (b) the Federal Funds Rate (as defined in the Credit Agreement) plus 0.50% per annum, and (c) the LIBOR Quoted Rate (as defined in the Credit Agreement) plus 1.00% per annum, in each case, with a floor of 1.75% per annum), plus variable spreads ranging from 1.75% to 2.50% per annum based on first lien net leverage ratio levels. Accrued and unpaid interest is payable with respect to LIBOR loans on the last day of the interest period as selected by the Company but no later than three months, and with respect to Alternate Base Rate Loans, quarterly on the last business day of each of March, June, September and December.
CY2021 us-gaap Line Of Credit Facility Commitment Fee Description
LineOfCreditFacilityCommitmentFeeDescription
An unused commitment fee is also payable with respect to the revolving credit facility and the delayed draw term loan facility ranging between 0.35% and 0.50% depending on the Company’s first lien net leverage ratio, and is payable quarterly in arrears with respect to the revolving credit facility and on the earliest of the termination of the delayed draw term loan facility, the six month anniversary of the Closing Date with respect to any delayed draw term loan commitments that have expired and otherwise after the end of the first full fiscal quarter after the Closing Date.
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6275000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6265000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
8611000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
11726000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
89063000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
121940000
CY2021Q2 cmax Capital Stock Par Or Stated Value Per Share
CapitalStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
261000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021 cmax Payment Of Offering Costs
PaymentOfOfferingCosts
12800000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
131000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.82
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
131000
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
5.82
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1341000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
0
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1300000
CY2021 cmax Remaining Earnout Shares Excluded From Computation Of Basic Net Income Loss Per Share
RemainingEarnoutSharesExcludedFromComputationOfBasicNetIncomeLossPerShare
3200000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-6675000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
7601000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52620980
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10796069
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52620980
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10796069
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.70
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.70
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
20800000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021 cmax Lessee Operating Lease Expiring Term Description
LesseeOperatingLeaseExpiringTermDescription
various times through 2031
CY2021 cmax Lessee Operating Lease Expiring Year
LesseeOperatingLeaseExpiringYear
2036
CY2021 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
21000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
10087000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10028000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
9715000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
9374000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
8685000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
58763000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
106652000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
7200000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
126000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
33000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
159000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.049
CY2021 cmax Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent
0.142
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.002
CY2021 cmax Effective Income Tax Rate Reconciliation Paycheck Protection Program Loan Forgiveness Percent
EffectiveIncomeTaxRateReconciliationPaycheckProtectionProgramLoanForgivenessPercent
0.081
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.221
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.025
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2257000
CY2021Q4 cmax Deferred Tax Assets Warrant Liabilities
DeferredTaxAssetsWarrantLiabilities
2219000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15982000
CY2021Q4 cmax Deferred Tax Assets Interest Carryforward
DeferredTaxAssetsInterestCarryforward
6962000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27420000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26128000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1292000
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1480000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
18000
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
219000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1717000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
425000
CY2021Q2 cmax Operating Loss Carryforwards Subject To Limitation
OperatingLossCarryforwardsSubjectToLimitation
43900000
CY2021Q2 cmax Operating Loss Carryforwards Subject To Business Expense Limitation
OperatingLossCarryforwardsSubjectToBusinessExpenseLimitation
21900000
CY2021 cmax Goodwill Amortization Period For Tax Purpose
GoodwillAmortizationPeriodForTaxPurpose
P15Y
CY2021Q4 cmax Unrecognized Tax Benefits Reserve
UnrecognizedTaxBenefitsReserve
0
CY2021 us-gaap Malpractice Insurance Maximum Coverage Per Incident
MalpracticeInsuranceMaximumCoveragePerIncident
1000000.0
CY2021 us-gaap Malpractice Insurance Annual Coverage Limit
MalpracticeInsuranceAnnualCoverageLimit
3000000.0
CY2021Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
0
CY2020Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
0

Files In Submission

Name View Source Status
0000950170-22-003946-index-headers.html Edgar Link pending
0000950170-22-003946-index.html Edgar Link pending
0000950170-22-003946.txt Edgar Link pending
0000950170-22-003946-xbrl.zip Edgar Link pending
cmax-20211231.htm Edgar Link pending
cmax-20211231.xsd Edgar Link pending
cmax-20211231_cal.xml Edgar Link unprocessable
cmax-20211231_def.xml Edgar Link unprocessable
cmax-20211231_htm.xml Edgar Link completed
cmax-20211231_lab.xml Edgar Link unprocessable
cmax-20211231_pre.xml Edgar Link unprocessable
cmax-ex21_1.htm Edgar Link pending
cmax-ex23_1.htm Edgar Link pending
cmax-ex31_1.htm Edgar Link pending
cmax-ex31_2.htm Edgar Link pending
cmax-ex32_1.htm Edgar Link pending
cmax-ex32_2.htm Edgar Link pending
cmax-ex4_4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img229435624_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending